Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)

08/05/2021 | 09:42am EDT

Item 8.01 - Other Events.

On June 9, 2021, OpGen, Inc. (the "Company") held its 2021 annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting was adjourned solely with respect to proposal 2 relating to the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of capital stock from 60,000,000 to 110,000,000 shares and authorized number of shares of common stock from 50,000,000 to 100,000,000 shares. On August 4, 2021, the Company determined to withdraw proposal 2 from stockholder consideration and therefore cancel the adjourned portion of the Annual Meeting. All other proposals were approved at the Annual Meeting, as previously reported on the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2021. The Company issued a press release announcing such cancellation of the adjourned portion of the Annual Meeting on August 4, 2021. A copy of such press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

99.1 Press release, dated August 4, 2021.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
10/15OPGEN : Announces $15 Million Registered Direct Offering - Form 8-K
PU
10/15OPGEN INC : Entry into a Material Definitive Agreement, Material Modification to Rights of..
AQ
10/14OPGEN : Launches $15 Million Registered Direct Offering
MT
10/14OPGEN : Announces $15 Million Registered Direct Offering
AQ
10/08OPGEN : Corporate Presentation (PDF)
PU
10/04Wall Street Set for Losses, Supply Chain Woes Dent Sentiment
MT
10/04Health Care Stocks Trade Lower Pre-Bell Monday
MT
10/04OPGEN : Health Care
MT
10/04OPGEN : Receives FDA Clearance for Launch of Acuitas AMR Gene Panel; Provides Preliminary ..
MT
10/04OPGEN : Corporate Presentation (PDF)
PU
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,90 M - -
Net income 2021 -38,4 M - -
Net Debt 2021 7,16 M - -
P/E ratio 2021 -1,92x
Yield 2021 -
Capitalization 77,7 M 77,7 M -
EV / Sales 2021 21,8x
EV / Sales 2022 8,26x
Nbr of Employees 102
Free-Float 99,8%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,03 $
Average target price 5,00 $
Spread / Average Target 146%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-0.49%78
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414